Get started
Author

Guadalupe Nibeyro

Observed name: Nibeyro, Guadalupe
ORCID: 0000-0001-5428-6321
Observed ORCID: 0000-0001-5428-6321
OpenAlex ID: A5076544207
Unraveling tumor specific neoantigen immunogenicity prediction: a comprehensive analysis
2023 · Guadalupe Nibeyro, Veronica Baronetto, et al. · Frontiers in Immunology · 23
PDF
MHC-I binding affinity derived metrics fail to predict tumor specific neoantigen immunogenicity
2022 · Guadalupe Nibeyro, Romina Girotti, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 6
PDF
Comprehensive evaluation of AlphaFold/OpenFold prediction of experimentally unresolved proteins through novel metrics
2026 · Florencia R Díaz, Daniela Orschanski, et al. · Briefings in Bioinformatics · 1
Immune Single-Cell Annotation by Molecular Signature-Based Deconvolution with MIXTURE
2025 · Agustin Nava, Guadalupe Nibeyro, et al. · Methods in molecular biology · 1
The Immunogenic Tumor-Specific Neoantigen Database (ITSNdb): A Tool for Comprehensive Performance Evaluation of Neoantigen Immunogenicity Predictors
2025 · Guadalupe Nibeyro, Rocío Flesia, et al. · Methods in molecular biology · 1
Estudio de variantes estructurales genómicas generadoras de neoantígenos de relevancia como biomarcadores en inmunoterapia tumoral
2026 · Nibeyro, Guadalupe · Repositorio Digital de la UNC (National University of Cordoba)
Figure 4 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Figure 5 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Supporting_Information from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Figure 2 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table_S4 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Figure 6 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table 1 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table_S3 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table_S5 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table S1 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Data from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Figure 3 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Table_S2 from Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al.
Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade–Treated Advanced Melanoma: A Retrospective Analysis
2025 · Guadalupe Nibeyro, Verónica M. Baronetto, et al. · Cancer Research Communications
Works count: 22
Citation count: 32
H-index: 2
I10-index: 1
Year
Topic
Type